Inflammatory condition of skin

This section encompasses a wide range of skin conditions, comprising a number of separate aetiologies. They fall into this category due to their common inflammatory pathology,

...


Read more on Inflammatory condition of skin

 

 

Latest news articles

Added 2 days ago Drug news

Sandoz presents switching data from Phase III studies of its biosimilar Zessly (infliximab) and biosimilar Erelzi (etanercept)showing the biosimilars match their reference biologics.

Sandoz, a Novartis division and the pioneer and global leader in biosimilars, announced the presentation of two long-term, Phase III...

Added 10 days ago Drug news

FDA approves Rituxan to treat severe pemphigus vulgaris.- Genentech/Roche.

Genentech, a member of the Roche Group announced that the FDA has approved Rituxan (rituximab) for the treatment of adults...

Added 16 days ago Drug news

CHMP recommends biosimilar adalimumab to treat all indications of the reference product.- Sandoz.

Sandoz, a Novartis division and the global leader in biosimilars, announced that the Committee for Medicinal Products for Human Use...

Search all news articles for Inflammatory condition of skin
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

IL-17A in Psoriasis

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress.

+ 1 more

Load more

Guidelines

S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 2 – Special patient populations and treatment situations

The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. The guideline is based on a systematic literature review completed on December 1, 2016, and on a formal consensus and approval process.

Added 4 days ago

British Association of Dermatologists’ guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018

The overall objective of the guidelines is to provide up-todate, evidence-based recommendations on the investigation and management of secondary pruritus without underlying skin disorder and generalized pruritus of unknown origin (GPUO) in adults...

Added 3 months ago

European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.

In addition to the interventions discussed in the update, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved apremilast and secukinumab as new treatment options for psoriasis.

Added 4 days ago

Search all guidelines for Inflammatory condition of skin
 

Journal articles

A safety evaluation of Guselkumab for the treatment of psoriasis.

Areas covered: In the following article, the mechanism of action and mainly the efficacy and safety profile of guselkumab available from results of trials will be discussed.

Added 4 days ago

Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals.

Objective: The aim of this study was to survey a group of Spanish dermatologists with particular expertise in the management of psoriasis to determine their opinions on the protocols used in routine clinical practice.

Added 4 days ago

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.

Background: Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis.

Added 4 days ago

Search all journal articles for Inflammatory condition of skin
 

Clinical trials

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA)...

Added 1 year ago

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Added 1 year ago

Search all clinical trials for Inflammatory condition of skin
 
Alex Keen

Alex studied Biological Sciences at university before joining EPG Health in January 2017, where he works as a digital content manager and editor.

In his spare time, Alex enjoys relaxing with a cool pint in the company of good friends. 

EULAR 2018 – Biosimilars: the future of rheumatology?

EULAR's Annual European Congress of Rheumatology aims to encourage innovation and collaboration across all aspects of rheumatology, something that is particularly well illustrated by biologics and their more affordable counterpart, biosimilars. Could they unlock the door to accessible, life-changing treatment for millions more?

CME

Psoriasis: diagnosis and individualised therapy

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
15

Ask an expert: Psoriasis

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Psoriasis: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
Search all CME for Inflammatory condition of skin